BC
ALLO icon

BIT Capital’s Allogene Therapeutics ALLO Stock Holding History

BIT Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$478K Buy
+230,000
New +$505K 0.01% 90

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BIT Capital's ALLO Position: Q2 2026 in Review

BIT Capital opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 230,000 shares worth $478K. The stake represents 0.01% of the portfolio and ranks #90 among its holdings.

209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • BIT Capital held 230,000 shares of Allogene Therapeutics worth $478K as of Q2 2026.
  • Allogene Therapeutics was a new BIT Capital position in Q2 2026.
  • Allogene Therapeutics made up 0.01% of BIT Capital's portfolio in Q2 2026, its #90 holding.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on BIT Capital's 13F filing for Q2 2026, filed 12 Aug 2026.